JP2021529814A5 - - Google Patents
Info
- Publication number
- JP2021529814A5 JP2021529814A5 JP2021500661A JP2021500661A JP2021529814A5 JP 2021529814 A5 JP2021529814 A5 JP 2021529814A5 JP 2021500661 A JP2021500661 A JP 2021500661A JP 2021500661 A JP2021500661 A JP 2021500661A JP 2021529814 A5 JP2021529814 A5 JP 2021529814A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- cycloalkyl
- heterocycloalkyl
- alkyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695384P | 2018-07-09 | 2018-07-09 | |
| US62/695,384 | 2018-07-09 | ||
| PCT/IB2019/055811 WO2020012339A1 (en) | 2018-07-09 | 2019-07-08 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529814A JP2021529814A (ja) | 2021-11-04 |
| JP2021529814A5 true JP2021529814A5 (cg-RX-API-DMAC7.html) | 2022-07-15 |
Family
ID=67997654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500661A Pending JP2021529814A (ja) | 2018-07-09 | 2019-07-08 | 化学化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210253528A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3820843A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021529814A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112424167A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021000332A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3105942A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020012339A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301709B2 (en) | 2017-08-09 | 2025-07-01 | Denali Therapeutics Inc | Compounds, compositions and methods |
| TW201920129A (zh) | 2017-09-01 | 2019-06-01 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| JP2021508336A (ja) | 2017-12-13 | 2021-03-04 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
| US11166942B2 (en) | 2018-06-05 | 2021-11-09 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| TW202545902A (zh) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| PH12021552759A1 (en) * | 2019-04-30 | 2022-07-04 | Abbvie Inc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| KR20220151635A (ko) | 2020-03-11 | 2022-11-15 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| CA3195290A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| MX2023004677A (es) | 2020-10-22 | 2023-05-24 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| ES2997335T3 (en) | 2020-10-22 | 2025-02-17 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| TW202241857A (zh) | 2020-12-18 | 2022-11-01 | 美商戴納立製藥公司 | 化合物之固體形式 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| EP1525185A1 (en) * | 2002-07-24 | 2005-04-27 | PTC Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007109107A2 (en) * | 2006-03-17 | 2007-09-27 | The Trustees Of Columbia University In The City Of New York | Atf4 as a therapeutic target in alzheimers disease and other neurological disorders |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| WO2014144952A2 (en) | 2013-03-15 | 2014-09-18 | Peter Walter | Modulators of the eif2alpha pathway |
| HUE046660T2 (hu) * | 2014-07-02 | 2020-03-30 | Inflectis Bioscience | O-alkil-benzilidén-guanidin-származékok és terápiás alkalmazás a rendellenes harmadlagos szerkezetû proteinek felhalmozódásával összefüggõ zavarok kezelésére |
| JP2017197433A (ja) * | 2014-09-12 | 2017-11-02 | 石原産業株式会社 | ニコチン酸エステル化合物、農園芸用殺菌剤及び植物病害の防除方法 |
| TWI920577B (zh) * | 2016-05-05 | 2026-04-01 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| RU2018145734A (ru) * | 2016-06-08 | 2020-07-14 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения в качестве ингибиторов atf4 пути |
| CN110730777A (zh) * | 2017-06-07 | 2020-01-24 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4通路抑制剂的化学化合物 |
| WO2019008506A1 (en) * | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
-
2019
- 2019-07-08 JP JP2021500661A patent/JP2021529814A/ja active Pending
- 2019-07-08 CA CA3105942A patent/CA3105942A1/en active Pending
- 2019-07-08 BR BR112021000332-0A patent/BR112021000332A2/pt not_active Application Discontinuation
- 2019-07-08 WO PCT/IB2019/055811 patent/WO2020012339A1/en not_active Ceased
- 2019-07-08 EP EP19770173.3A patent/EP3820843A1/en not_active Withdrawn
- 2019-07-08 CN CN201980046203.5A patent/CN112424167A/zh active Pending
- 2019-07-08 US US16/973,587 patent/US20210253528A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521111A5 (cg-RX-API-DMAC7.html) | ||
| JP2019521109A5 (cg-RX-API-DMAC7.html) | ||
| RU2018146946A (ru) | Химические соединения | |
| RU2018145734A (ru) | Химические соединения в качестве ингибиторов atf4 пути | |
| JP7158382B2 (ja) | C-kit阻害剤としてのアミノチアゾール化合物 | |
| JP2023518286A5 (cg-RX-API-DMAC7.html) | ||
| JP5978293B2 (ja) | Namptを阻害するための新規な化合物および組成物 | |
| JP6227707B2 (ja) | Mcl‐1を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。 | |
| AU2014222756B2 (en) | Inhibitors of histone demethylases | |
| US11932647B2 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| CN103261160A (zh) | 用于抑制nampt的胍化合物和组合物 | |
| KR100737090B1 (ko) | 축합 이미다졸륨 유도체 | |
| RU2018113430A (ru) | Производные l-фенилпирролидин-2-она в качестве ингибиторов perk | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2022504949A5 (cg-RX-API-DMAC7.html) | ||
| JP2021512059A5 (cg-RX-API-DMAC7.html) | ||
| US9255072B2 (en) | Pyrazole compounds and thiazole compounds as protein kinases inhibitors | |
| JPH11269146A (ja) | 分化誘導剤 | |
| JP2017537948A5 (cg-RX-API-DMAC7.html) | ||
| US20150284347A1 (en) | New benzene sulfonamide thiazole compounds | |
| JP2020534373A5 (cg-RX-API-DMAC7.html) | ||
| JP2021529814A (ja) | 化学化合物 | |
| TW202003487A (zh) | 經取代的2,2'—聯嘧啶基化合物、其類似物及其使用方法 | |
| JP2025081626A (ja) | ペンタミジンの類似体及びその使用 | |
| JP2023538159A5 (cg-RX-API-DMAC7.html) |